ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BMS-986310

Also written as “ONO-4578”.

Its studies are mostly in Stomach Neoplasms · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms, led by 2 companies.

Drug pageBMS-986310: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 9, 20266 company-led studies, 4 open or runningNext primary completion: Feb 15, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ono Pharmaceuticalits history only54 open or runningphase 3since Sep 9, 2026Mar 17, 2017Feb 15, 2028phase 2 · NCT06948448
Bristol-Myers Squibb10 open or runningphase 1since Aug 30, 2018Aug 30, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 30, 2018First study: phase 1 study in Advanced CancerFirst studyNCT03661632 · 27 enrolled · United States, Belgium, Canada

TargetBeta

PTGER4 →read by rule
“An orally bioavailable antagonist of the prostaglandin E2 receptor subtype 4 (PTGER4; EP4), ”NCIt, by rule

Other programs on PTGER4

ProgramCompanyFurthest phaseStudies
EP4 Receptor Antagonist YY001rulechongqing-claruvis-pharmaceutical-co-ltdphase 36
EP2/EP4/DP1 Antagonist OKN4395ruleepkinphase 11

Studies

The one study Bristol-Myers Squibb leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03661632Advanced Cancer · United States, Belgium, Canada1CompletedNov 11, 201927

How it is read

Names in the registry

  • “ONO-4578”, 5 entries
  • “BMS-986310”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.